Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy

Blood Pressure

Volumn 19, Issue 1, 2010, Pages 40-47

  Xiaozhen, Huang ^a   Yun, Zhang ^a   Mei, Zhang ^a   Yu, Sun ^b  

^a SHANDONG UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Endothelin 1; Endothelium dependent and independent vasodilation; Left ventricular mass index; Transesophageal echocardiography

Indexed keywords

CARVEDILOL; CARVEDILOL TARTRATE; DIPYRIDAMOLE; ENDOTHELIN 1; METOPROLOL; NITRIC OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD FLOW VELOCITY; BLOOD LEVEL; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE MASS INDEX; HEART RATE; HUMAN; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VERTIGO;

ADMINISTRATION, SUBLINGUAL; ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRACHIAL ARTERY; CARBAZOLES; CORONARY CIRCULATION; DIASTOLE; DIPYRIDAMOLE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INJECTIONS, INTRAVENOUS; MALE; METOPROLOL; MIDDLE AGED; NITROGLYCERIN; PROPANOLAMINES; VASODILATION; VASODILATOR AGENTS;

EID: 77649166914     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903450492     Document Type: Article

References (34)

1. Nemes A, Neu K, Forster T, Kovacs Z, Csanady M. Coronary flow velocity reserve is diminished in hypertensive left ventricular hypertrophy. Kardiol Pol. 2005;62:1-5.
2. Caliskan M, Erdogan D, Gullu H, Ciftci O, Yildirim I, Baycan S, et al.. Association between serum gammaglutamyltransferase levels and coronary microvascular function in hypertensive patients. J Hypertens. 2007;25: 2497-2503. (Pubitemid 350060389)
3. Chen D, Lin J, Chen J. In patients with hypertensive left ventricular hypertrophy and coronary heart disease, coronary flow reserve is similarly impaired. Chin Med Sci J. 1995; 10:151-157.
4. Kim W, Jeong MH, Cha KS, Hyun DW, Hur SH, Kim KB, et al.. Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J. 2005; 69:101-106.
5. Cargnoni A, Ceconi C, Bernocchi P, Boraso A, Parrinello G, Curello S, et al.. Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability. Cardiovasc Res. 2000;47:556-566.
6. Nakajima T, Ma J, Iida H, Iwasawa K, Jo T, Omata M, et al.. Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells. Jpn Heart J. 2003;44:963-978.
7. Fujio H, Nakamura K, Matsubara H, Kusano KF, Miyaji K, Nagase S, et al.. Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2006;47:250-255.
8. Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, et al.. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: Effects of smoking. Am J Hypertens. 2004;17:582-589.
9. Oettl K, Greilberger J, Zangger K, Haslinger E, Reibnegger G, Jürgens G. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol. 2001;62:241-248.
10. Jonsson G, Abdelnoor M, Seljeflot I, Arnesen H, Hostmark AT, Kjeldsen SE, et al.. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol. 2007;49:27-32.
11. Jonsson G, Fossum E, Kjeldsen SE, Høieggen A, Os I, Eide I, et al.. Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11:377-384.
12. Koepfli P, Wyss CA, Namdar M, Klainguti M, von Schulthess GK, Lüscher TF, et al.. Beta adrenergic blockade and myocardial perfusion in coronary artery disease: Differential effects in stenotic versus remote myocardial segments. J Nucl Med. 2004;45:1626-1631.
13. Kveiborg B, Major-Petersen A, Christiansen B, Torp- Pedersen C. Carvedilol in the treatment of chronic heart failure: Lessons from the Carvedilol Or Metoprolol European Trial. Vasc Health Risk Manag. 2007;3:31-37. Review.
14. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez- Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20:777-783.
15. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr control trials Cardiovasc Med. 2001;2:20-23.
16. Walther G, Nottin S, Karpoff L, Pérez-Martin A, Dauzat M, Obert P. Flow-mediated dilation and exercise-induced hyperaemia in highly trained athletes: Comparison of the upper and lower limb vasculature. Acta Physiol (Oxf). 2008;193: 139-150.
17. Caliskan M, Erdogan D, Gullu H, Ciftci O, Yildirim I, Baycan S, et al.. Association between serum gamma-glutamyltransferase levels and coronary microvascular function in hypertensive patients. J Hypertens. 2007;25:2497-2503. (Pubitemid 350060389)
18. Galderisi M, Cicala S, D'Errico A, De Divitiis O, De Simone G. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens. 2004; 22:2201-2208.
19. Rozenberg VD, Nepomnyashchikh LM. Pathomorphology of variant relationships between left ventricle and interventricular septum in hypertensive heart. Bull Exp Biol Med. 2007;144:103-107.
20. Palmieri V, Storto G, Arezzi E, Pellegrino T, Mancini M, Di Minno G, et al.. Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects. J Hum Hypertens. 2005;19:941-950.
21. Galderisi M, Cicala S, De Simone L, Caso P, Petrocelli A, Pietropaolo L, et al.. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy. Ital Heart J. 2001;2:677-684.
22. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Penno G, Pucci L, et al.. Peripheral wave refl ection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome. J Hypertens. 2008;26: 1216-1222.
23. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411-418.
24. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A-11A.
25. Mörtsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: The Swedish Irbesartan Left Ventricular Hypertrophy Inves tigation versus Atenolol (SILVHIA) study. J Intern Med. 2007;261:472-479.
26. Tedesco MA, Natale F, Mocerino R, Tassinario G, Zhang YJ, Xiang MX, et al.. Renal resistive index and cardiovascular organ damage in a large population of hypertensive patients. J Hum Hypertens. 2007;21:291-296.
27. De Gregorio C, Micari A, Grimaldi P, Bragadeesh T, Arrigo F, Coglitore S. Behavior of both epicardial and intramural coronary artery flow velocities in various models of myocardial hypertrophy: Role for left ventricular outflow tract obstruction. Am Heart J. 2005;149:1091-1098.
28. Takiuchi S, Rakugi H, Fujii H, Kamide K, Horio T, Nakatani S, et al.. Carotid intima-media thickness is correlated with impairment of coronary flow reserve in hypertensive patients without coronary artery disease. Hypertens Res. 2003;26:945-951.
29. Galderisi M, de Simone G, D'Errico A, Sidiropulos M, Viceconti R, Chinali M, et al.. Independent association of coronary flow reserve with left ventricular relaxation and fi lling pressure in arterial hypertension. Am J Hypertens. 2008;21:1040-1046.
30. Khalil A, Sareen R, Mallika V, Chowdhury V. Non-invasive evaluation of endothelial function, arterial mechanics and nitric oxide levels in children of hypertensive parents. Indian Heart J. 2008;60:34-38.
31. Shirwany A, Weber KT. Extracellular matrix remodeling in hypertensive heart disease. J Am Coll Cardiol. 2006;48: 97-98.
32. Flamant M, Placier S, Dubroca C, Esposito B, Lopes I, Chatziantoniou C, et al.. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007; 50:212-218.
33. Grimm D, Huber M, Jabusch HC, Shakibaei M, Fredersdorf S, Paul M, et al.. Extracellular matrix proteins in cardiac fi broblasts derived from raThearts with chronic pressure overload: Effects of beta-receptor blockade. J Mol Cell Cardiol. 2001; 33:487-501.
34. Zhang YJ, Xiang MX, San J, Cheng G, Wang SS. Effect of matrine and carvedilol on collagen and MMPs activity of hypertrophy myocardium induced by pressure overload. J Zhejiang Univ Sci B. 2006;7:245-250.